
Please try another search
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101), seltorexant and MIN-301. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. The Company is developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders.
Name | Age | Since | Title |
---|---|---|---|
William F. Doyle | 59 | 2017 | Lead Independent Director |
Hans Peter Hasler | 65 | 2017 | Independent Director |
Fouzia Laghrissi-Thode | 58 | 2015 | Independent Director |
David J. Kupfer | 80 | 2015 | Independent Director |
Remy Luthringer | 60 | 2014 | Executive Chairman & CEO |
G. Jan van Heek | 71 | 2014 | Independent Director |
Jeryl Lynn Hilleman | 63 | 2018 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review